Experimental cancer drug combo trial halted early
NCT ID NCT06158958
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-stage study tested an experimental drug called ABBV-303, alone or with another drug (budigalimab), in adults with advanced solid tumors that had stopped responding to treatment. The goal was to check safety and see if the drugs could shrink tumors. The study was terminated early after enrolling 27 participants out of a planned 181.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina BioOncology Institute /ID# 254305
Huntersville, North Carolina, 28078, United States
-
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 266792
Irvine, California, 92618, United States
-
City of Hope /ID# 254303
Duarte, California, 91010, United States
-
Hadassah Medical Center-Hebrew University /ID# 254606
Jerusalem, 91120, Israel
-
NEXT Oncology /ID# 257395
San Antonio, Texas, 78229, United States
-
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 256943
New York, New York, 10016, United States
-
National Cancer Center Hospital /ID# 254359
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East /ID# 261712
Kashiwa-shi, Chiba, 277-8577, Japan
-
Rambam Health Care Campus /ID# 254608
Haifa, 3109601, Israel
-
START Midwest /ID# 256945
Grand Rapids, Michigan, 49546-7062, United States
-
Shizuoka Cancer Center /ID# 261714
Sunto-gun, Shizuoka, 411-8777, Japan
-
South Texas Accelerated Research Therapeutics /ID# 256944
San Antonio, Texas, 78229, United States
-
The Chaim Sheba Medical Center /ID# 259408
Ramat Gan, Tel Aviv, 5265601, Israel
-
The Ohio State University - The James /ID# 260475
Columbus, Ohio, 43210-1240, United States
-
University of Southern California /ID# 254356
Los Angeles, California, 90033, United States
-
University of Texas MD Anderson Cancer Center /ID# 254308
Houston, Texas, 77030, United States
-
Wakayama Medical University Hospital /ID# 254361
Wakayama, Wakayama, 641-8510, Japan
-
Washington University-School of Medicine /ID# 262943
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.